X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4947) 4947
humans (4569) 4569
oncology (4021) 4021
chemotherapy (2596) 2596
cancer (2014) 2014
female (2010) 2010
bevacizumab (1939) 1939
male (1563) 1563
antineoplastic combined chemotherapy protocols - therapeutic use (1546) 1546
middle aged (1413) 1413
aged (1410) 1410
treatment outcome (1291) 1291
1st-line treatment (1286) 1286
care and treatment (1238) 1238
antineoplastic agents - therapeutic use (1194) 1194
phase-iii trial (1191) 1191
colorectal cancer (1125) 1125
adult (1104) 1104
metastasis (1079) 1079
phase-ii trial (1041) 1041
colorectal neoplasms - drug therapy (910) 910
open-label (866) 866
research (793) 793
hematology, oncology and palliative medicine (785) 785
drug therapy (776) 776
medicine & public health (774) 774
pharmacology & pharmacy (762) 762
endothelial growth-factor (750) 750
survival (705) 705
colorectal neoplasms - pathology (703) 703
disease-free survival (689) 689
prognosis (689) 689
plus irinotecan (679) 679
fluorouracil (653) 653
cetuximab (646) 646
therapy (638) 638
clinical trials (631) 631
trial (631) 631
neoplasm metastasis (625) 625
lung neoplasms - drug therapy (619) 619
oxaliplatin (616) 616
angiogenesis inhibitors - therapeutic use (606) 606
health aspects (600) 600
double-blind (599) 599
aged, 80 and over (597) 597
metastatic colorectal-cancer (568) 568
angiogenesis (563) 563
antineoplastic combined chemotherapy protocols - adverse effects (563) 563
carcinoma, non-small-cell lung - drug therapy (554) 554
animals (539) 539
leucovorin (539) 539
analysis (537) 537
breast cancer (536) 536
antibodies, monoclonal - therapeutic use (527) 527
neoplasm staging (525) 525
randomized-trial (523) 523
growth-factor receptor (515) 515
vascular endothelial growth factor (511) 511
cancer therapies (508) 508
combination (498) 498
tumors (489) 489
clinical trials as topic (488) 488
surgery (471) 471
antibodies, monoclonal, humanized (470) 470
capecitabine (466) 466
paclitaxel (464) 464
antineoplastic agents (457) 457
breast neoplasms - drug therapy (446) 446
survival rate (440) 440
cell lung-cancer (428) 428
irinotecan (427) 427
antimitotic agents (425) 425
deoxycytidine - analogs & derivatives (425) 425
randomized phase-iii (412) 412
randomized controlled trials as topic (399) 399
patients (398) 398
docetaxel (397) 397
retrospective studies (393) 393
review (393) 393
mutation (392) 392
fluorouracil - administration & dosage (390) 390
molecular targeted therapy (390) 390
development and progression (387) 387
targeted therapy (386) 386
phase-iii (380) 380
survival analysis (367) 367
camptothecin - analogs & derivatives (362) 362
lung cancer (361) 361
phase-ii (356) 356
antineoplastic combined chemotherapy protocols - administration & dosage (353) 353
lung neoplasms - pathology (349) 349
immunotherapy (340) 340
1st-line therapy (335) 335
antineoplastic agents - adverse effects (335) 335
bevacizumab plus irinotecan (334) 334
cancer research (329) 329
disease progression (328) 328
cisplatin (326) 326
radiotherapy (324) 324
carboplatin (322) 322
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5810) 5810
French (55) 55
German (37) 37
Spanish (5) 5
Polish (4) 4
Korean (3) 3
Japanese (2) 2
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 24, pp. 3004 - 3011
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 02/2013, Volume 119, Issue 3, pp. 586 - 592
BACKGROUND: Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for... 
unresectable metastatic melanoma | combination therapy | chemotherapy | metastatic melanoma | vascular endothelial growth factor inhibition | SURVIVAL | CELLS | MALIGNANT-MELANOMA | DACARBAZINE | PLUS PACLITAXEL | COMBINATION | UNTREATED ADVANCED MELANOMA | ONCOLOGY | PROGRESSION | ENDOTHELIAL GROWTH-FACTOR | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Carboplatin - adverse effects | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Albumins - adverse effects | Skin Neoplasms - mortality | Dacarbazine - analogs & derivatives | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Albumins - administration & dosage | Treatment Outcome | Melanoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Melanoma - mortality | Care and treatment | Usage | Patient outcomes | Melanoma | Causes of | Research | Temozolomide | Drug therapy, Combination | Vascular endothelial growth factor | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Anticancer Research, ISSN 0250-7005, 10/2017, Volume 37, Issue 10, pp. 5553 - 5558
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 12/2013, Volume 119, Issue 23, pp. 4180 - 4187
Journal Article
Journal Article